Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Targeting BKCa Channels in Migraine: Rationale and Perspectives

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Debate: Are cluster headache and migraine distinct headache disorders?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. The Role of High-Conductance Calcium Activated Potassium Channel in Headache and Migraine Pathophysiology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Large (big)-conductance calcium-activated potassium (BKCa) channels are expressed in migraine-related structures such as the cranial arteries, trigeminal ganglion and trigeminal spinal nucleus, and they play a substantial role in vascular tonus and neuronal excitability. Using synthetic BKCa channels openers was associated with headache as a frequent adverse effect in healthy volunteers. Additionally, BKCa channels are downstream molecules in migraine signalling pathways that are activated by several compounds known to provoke migraine, including calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP) and glyceryl trinitrate (GTN). Also, there is a high affinity and a close coupling between BKCa channels and ATP-sensitive potassium (KATP) channels, the role of which has recently been established in migraine pathophysiology. These observations raise the question as to whether direct BKCa channel activation can provoke migraine in migraine patients, and whether the BKCa channel could be a potential novel anti-migraine target. Hence, randomized and placebo-controlled clinical studies on BKCa channel openers or blockers in migraine patients are needed.

OriginalsprogEngelsk
TidsskriftCNS Drugs
Vol/bind34
Udgave nummer4
Sider (fra-til)325-335
Antal sider11
ISSN1172-7047
DOI
StatusUdgivet - apr. 2020

ID: 59482800